Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial.
The use of <i>S. mirzayanii</i> as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve <i>H. pylori</i>eradication rate.
Authors
- Nima Vaziri (ORCID: https://orcid.org/0000-0001-9419-8414)
- Fatemeh Dabaghzadeh
- Bijan Ahmadi (ORCID: https://orcid.org/0000-0002-8504-6686)
- Gholamreza Dehghannoudeh (ORCID: https://orcid.org/0000-0003-1420-2650)
- Farhad Sarafzadeh
- Fariba Sharififar (ORCID: https://orcid.org/0000-0002-9057-1987)
Institutions
- Kerman University of Medical Sciences (IR)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.19852/j.cnki.jtcm.2025.02.009
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00